LV-KL

International, multicenter, and prospective trials for treatment of HCC

Pierce Kah Hoe CHOW*

Division of Surgery and Surgical Oncology, Department of Hepato-Pancreato-Biliary and Transplant Surgery,
Singapore General Hospital and National Cancer Centre Singapore, Singapore

Lecture: The clinical outcomes of hepatocellular carcinoma still lag behind those of other common cancers such as colorectal and breast cancers. Specifically, there is currently no adjuvant or neoadjuvant therapy in HCC. Pivotal clinical trials are thus needed to address important management issues in HCC.

The last few years has seen positive phase III trials with systemic therapy in advanced HCC including immunotherapy combination. These has thus provided impetus for a range of clinical trials in HCC addressing adjuvant and neoadjuvant therapies in resected HCC, loco-regional therapy combinations in intermediate/locally advanced HCC and systemic combination therapies in advanced HCC. Current pivotal prospective multinational trials for these indications are discussed.

Corresponding Author: Pierce Kah Hoe CHOW (lynette.lai.soh.han@nccs.com.sg)

Presenter: Pierce Kah Hoe CHOW (lynette.lai.soh.han@nccs.com.sg)

Copyright © The Korean Association of Hepato-Biliary-Pancreatic Surgery

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.